Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan to Officially Sign Up for COVAX Pact; Govt to Hammer Out Payment on Sept. 15
The Japanese government has decided to officially commit to joining the COVAX facility, a WHO-led global pact for the joint procurement of COVID-19 vaccines, eyeing the allocation of 10-20 billion yen for an upfront payment due by October 9, according…
To read the full story
Related Article
- Japan Inks COVAX Pact with Optional Arrangement, Commits 17.2 Billion Yen Upfront
September 16, 2020
- Japan Weighs COVAX Participation with Optional Purchase Arrangement
September 2, 2020
- Japan Discussing Participation in COVAX Pact: Sr. Health Vice Minister
August 20, 2020
- Komeito Nudges Govt to Join COVAX Pact for Coronavirus Vaccine Procurement
August 19, 2020
REGULATORY
- Measles Cases Surge Past Last Year’s Total, Minister Vows Coordinated Response
April 27, 2026
- H5N1 Pre-Pandemic Flu Vaccine Strain Re-Selected for FY2026 Stockpiling
April 27, 2026
- JIHS Inks MOU with German Network to Boost Infectious Disease Preparedness
April 27, 2026
- Govt Presents Draft Public-Private Investment Roadmap at Growth Strategy WG
April 27, 2026
- LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…